CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 4 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01069341
NCT01069341Phase 1Completed
CompareCT.gov

Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)

Bhagat, Neelakshi, M.D., M.P.H.·interventional·Posted Feb 17, 2010·Updated Oct 4, 2012

In Brief

A Phase 1 clinical trial evaluating Ranibizumab for Rubeosis Iridis and Proliferative Diabetic Retinopathy. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRubeosis Iridis, Proliferative Diabetic Retinopathy
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 17, 2010
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 16.4 years ago

Interventions

Ranibizumabdrug

Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.